Tryp Therapeutics CEO Greg Mckee joined Proactive to discuss next steps that group will take following its Investigational New Drug submission to the FDA for its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders.
Mckee says the San Diego, California-based pharmaceutical company should be in a position to file its remaining three INDs in its third or fourth quarter, along with subsequent news flow including first patient dose and data readouts.